ALUMIS INC. (ALMS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-30

Key Insights

Alumis reported positive topline results from two Phase 3 trials of its lead drug candidate envudeucitinib for the treatment of plaque psoriasis, showing early and robust improvements in skin clearance, quality of life, and psoriasis symptoms.
The company plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026, which could potentially transform the treatment landscape for IL-23/IL-17-driven diseases as well as those driven by Type I interferon.
Alumis expects to have one-year Phase 3 long-term data available in the second half of 2026 and is also developing a once-daily formulation and a pediatric development plan for envudeucitinib, further expanding its commercial potential.

Want the newest filings?

This analysis covers the filing from 2026-03-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-19

Alumis Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during the previous fiscal year.
The filing does not provide any details on the company's financial results or other material information, limiting the ability to assess the company's current state and future prospects.
Without further details on the company's operational and financial performance, it is difficult to determine the overall significance of this filing for investors.

Filed: 2026-01-09

Alumis Inc. reported preliminary unaudited cash, cash equivalents and marketable securities of approximately $308.6 million as of December 31, 2025, providing insight into the company's strong liquidity position.
Alumis announced a public offering of 17,650,000 shares of its common stock at $17.00 per share, raising approximately $345.1 million in gross proceeds before deductions, which will strengthen the company's financial flexibility.
The company granted the underwriters an option to purchase up to an additional 2,647,500 shares, which was exercised in full, further increasing the total capital raised through the offering.

Filed: 2026-01-02

Alumis Inc. has filed an 8-K report indicating a material breach by its partner Climb Bio, who has failed to make a $3 million development milestone payment as required under their asset purchase agreement.
Alumis intends to pursue all available legal rights and remedies against Climb Bio, including seeking the overdue payment, interest, and reimbursement of legal fees.
The dispute appears to center around Climb Bio's claim that its drug candidate 'budoprutug' does not qualify as a 'Product' under the agreement, contrary to Climb Bio's own prior statements.

Other reports for ALUMIS INC.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.